![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
DexCom
DXCM
Hutchmed (China)
HCM
New Fortress Energy
NFE
Enerpac Tool
EPAC
US Stock MarketDetailed Quotes
ADAP Adaptimmune Therapeutics
- 0.578
- +0.002+0.26%
Close Feb 14 16:00 ET
- 0.589
- +0.011+1.82%
Post 20:01 ET
147.90MMarket Cap-3.46P/E (TTM)
0.598High0.562Low310.95KVolume0.562Open0.577Pre Close180.79KTurnover0.16%Turnover RatioLossP/E (Static)255.88MShares2.05052wk High1.85P/B113.37MFloat Cap0.53252wk Low--Dividend TTM196.14MShs Float21.570Historical High--Div YieldTTM6.25%Amplitude0.420Historical Low0.581Avg Price1Lot Size
Adaptimmune Therapeutics Stock Forum
Sign in to post a comment
$Adaptimmune Therapeutics (ADAP.US)$ .. once open will turn to red!!
1
$Adaptimmune Therapeutics (ADAP.US)$
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
Monday, 13th January at 8:00 am
The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other cell therapy pipeline assets
Adaptimmune Allo-T program to be featured at the Biotech ShowCase(TM) and the
Wuxi Global Forum ...
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
Monday, 13th January at 8:00 am
The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other cell therapy pipeline assets
Adaptimmune Allo-T program to be featured at the Biotech ShowCase(TM) and the
Wuxi Global Forum ...
2
$Adaptimmune Therapeutics (ADAP.US)$ .. Only green for pre- market !!!
Note: This seems to be a long list. The rationale is that I al focused on at least 20% gains and not just after bangers. My trading style is to compound those 10-15-20-30% earnings and roll all profit rather than waiting for runners everyday. If runners appear, then I’ll grab it as well. Each has his own style earning.
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...
35
19
5
$Adaptimmune Therapeutics (ADAP.US)$ First Patient Treated With Adaptimmune's TECELRA(R) (Afamitresgene Autoleucel)
newsfile· 2 mins ago
Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma
newsfile· 2 mins ago
Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma
$Adaptimmune Therapeutics (ADAP.US)$ Plus DATA to be presented for IGNYTE-ESO Trial of LETE-CEL in patients with SYNOVIAL SARCOMA! on 11/16/24 Saturday at CTOS annual meeting! ((((. Financial Results for the three and nine months ended September 30, 2024
● Cash / liquidity position: As of September 30, 2024, Adaptimmune had cash and cash equivalents of $116.7 million and Total Liquidity2 of $186.1 million, compared to $144.0 million and $146.9 million respectively, as of December 31...
● Cash / liquidity position: As of September 30, 2024, Adaptimmune had cash and cash equivalents of $116.7 million and Total Liquidity2 of $186.1 million, compared to $144.0 million and $146.9 million respectively, as of December 31...
1
$Adaptimmune Therapeutics (ADAP.US)$ .. green when is the pre-market , will drop once open market!!!
2
1
$Adaptimmune Therapeutics (ADAP.US)$ Item 1.01Entry into a Material Definitive Agreement.
On September 23, 2024, Adaptimmune Therapeutics plc (the “Company”) entered into a Mutual Release and Resolution Agreement (the “Agreement”) with Genentech Inc and F. Hoffmann-La Roche Ltd, (together “Genentech”). The parties entered into the Agreement following notice of termination of their Collaboration and License Agreement dated September 3, 2021 (the “Collaboration Agreement”) on April 8,...
On September 23, 2024, Adaptimmune Therapeutics plc (the “Company”) entered into a Mutual Release and Resolution Agreement (the “Agreement”) with Genentech Inc and F. Hoffmann-La Roche Ltd, (together “Genentech”). The parties entered into the Agreement following notice of termination of their Collaboration and License Agreement dated September 3, 2021 (the “Collaboration Agreement”) on April 8,...
2
2
No comment yet
101674396 OP : this stock is a pre-market